Primary efficacy endpoint and occlusion assessment at 12 months
| Unruptured | Ruptured | Total | |
| Primary efficacy endpoint | n=93 | n=53 | n=146 |
| Raymond I | 52 (55.9%) | 38 (71.1%) | 90 (61.6%) |
| Raymond II | 23 (24.7%) | 7 (13.2%) | 30 (20.5%) |
| Raymond III | 18* (19.4%) | 8† (15.1%) | 26‡ (17.8%) |
| Adequate occlusion without re-treatment | 75 (80.6%) | 45 (84.9%) | 120 (82.2%) |
| Occlusion assessment at 12 months | n=91 | n=52 | n=143 |
| Raymond I | 52 (57.1%) | 38 (73.1%) | 90 (62.9%) |
| Raymond II | 23 (25.3%) | 7 (13.5%) | 30 (21.0%) |
| Raymond III | 16 (17.6%) | 7 (13.5%) | 23 (16.1%) |
| Adequate occlusion | 75 (82.4%) | 45 (86.5%) | 120 (83.9%) |
Primary efficacy endpoint consists of occlusion rate with no re-treatment at the 12 months' follow-up; for re-treated patients, occlusion rate was assessed at the time of re-treatment.
Occlusion assessment at the 12 months' follow-up is a secondary endpoint and does not include re-treated patients.
*Including two subjects re-treated.
†Including one subject re-treated.
‡Including three subjects re-treated.